MedTrace Logo

Efficacy of Polyglucosamine for Weight Loss

NCT02410785 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2016-01-28

No results posted yet for this study

Summary

The polyglucosamine, specification L112 is a medical device and in this clinical trial used for weight reduction of overweight and obese participants. The rationale for this study is to show that overweight can be reduced by taking 2 times daily 2 tablets with the main meals with the highest fat content.

Conditions

  • Overweight and Obesity

Interventions

DEVICE

Polyglucosamine

ß-1,4 polymer of D-glucosamine and N-acetyl-D-glucosamine from the shells of crustaceans

OTHER

Placebo

Placebo tablet

Sponsors & Collaborators

  • Certmedica International GmbH

    lead INDUSTRY

Principal Investigators

  • Karina Pokhis, MD · Salztal Klinik GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2009-10-31
Completion
2010-10-31

Countries

  • Germany
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02410785 on ClinicalTrials.gov